However, the comparably high fraction of p16 positive cases in our study using a single 0.6 mm TMA spot per cancer and earlier studies on conventional large sections argues against substantially heterogeneity of p16 expression in breast cancer. Here, CDKN2A is linked to breast carcinoma.